TearSolutions Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 10

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $15.7M

  • Investors
  • 11

TearSolutions General Information

Description

Developer of a peptide therapy designed for the treatment of signs and symptoms of dry eye in primary sjögren's syndrome patients. The company's product helps patient preserves all of the biological activity of a naturally occurring tear protein by introducing a short stable peptide that can be produced at scale and restore basal tearing without irritation and heal the corneal surface of the eye, providing patients with rapid improvement in corneal health and a reduction in symptoms of dry eyes.

Contact Information

Website
www.tearsolutions.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 315 Old Ivy Way
  • Suite 301
  • Charlottesville, VA 22903
  • United States
+1 (434)
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Vertical(s)
Life Sciences
Corporate Office
  • 315 Old Ivy Way
  • Suite 301
  • Charlottesville, VA 22903
  • United States
+1 (434)

TearSolutions Timeline

2021202220232024
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TearSolutions Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC (Series B) 21-Nov-2024 $15.7M Completed Generating Revenue
6. Later Stage VC 24-Jan-2022 Completed Generating Revenue
5. Later Stage VC (Series B2) 26-Feb-2020 Completed Clinical Trials - Phase 2
4. Later Stage VC (Series B2) 19-Mar-2019 Completed Clinical Trials - Phase 2
3. Early Stage VC (Series B) 06-Dec-2017 Completed Clinical Trials - Phase 2
2. Early Stage VC (Series A) 10-Nov-2015 $3M $3M Completed Startup
1. University Spin-Out 01-Jan-2013 Completed Startup
To view TearSolutions’s complete valuation and funding history, request access »

TearSolutions Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Series B2
Series B1
Series A 642,906 $0.001000 8% $5 $5 1x $5 9.66%
To view TearSolutions’s complete cap table history, request access »

TearSolutions Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a peptide therapy designed for the treatment of signs and symptoms of dry eye in primary sjögren's syndrome
Drug Discovery
Charlottesville, VA
10 As of 2024

Cambridge, United Kingdom
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TearSolutions Competitors (7)

One of TearSolutions’s 7 competitors is Exonate, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exonate Venture Capital-Backed Cambridge, United Kingdom
Gyroscope Formerly VC-backed London, United Kingdom
PulseSight Therapeutics Venture Capital-Backed Paris, France
Alnylam Pharmaceuticals Formerly VC-backed Cambridge, MA
ONL Therapeutics Venture Capital-Backed Ann Arbor, MI
You’re viewing 5 of 7 competitors. Get the full list »

TearSolutions Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 8

    Granted

  • 13

    Pending

  • Expiring in next 12 mo

TearSolutions Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3986914-A1 Constrained peptides Pending 19-Jun-2019
JP-2022537383-A Constrained peptide Pending 19-Jun-2019
AU-2020298164-A1 Constrained peptides Pending 19-Jun-2019
CA-3143676-A1 Constrained peptides Pending 19-Jun-2019
EP-3986914-A4 Constrained peptides Pending 19-Jun-2019 C07K14/001
To view TearSolutions’s complete patent history, request access »

TearSolutions Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TearSolutions Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Dave Metzak Angel (individual) Minority
Jim Cheng Angel (individual) Minority
UVA LVG Seed Fund Venture Capital Minority
CAV Angels Angel Group Minority
Pharmstandard Corporation Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

TearSolutions FAQs

  • When was TearSolutions founded?

    TearSolutions was founded in 2013.

  • Where is TearSolutions headquartered?

    TearSolutions is headquartered in Charlottesville, VA.

  • What is the size of TearSolutions?

    TearSolutions has 10 total employees.

  • What industry is TearSolutions in?

    TearSolutions’s primary industry is Drug Discovery.

  • Is TearSolutions a private or public company?

    TearSolutions is a Private company.

  • What is TearSolutions’s current revenue?

    The current revenue for TearSolutions is .

  • How much funding has TearSolutions raised over time?

    TearSolutions has raised $40.7M.

  • Who are TearSolutions’s investors?

    Dave Metzak, Jim Cheng, UVA LVG Seed Fund, CAV Angels, and Pharmstandard are 5 of 11 investors who have invested in TearSolutions.

  • Who are TearSolutions’s competitors?

    Exonate, Gyroscope, PulseSight Therapeutics, Alnylam Pharmaceuticals, and ONL Therapeutics are some of the 7 competitors of TearSolutions.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »